Source Fact: Financial Supervisory Service Electronic Disclosure System (DART) / 2025-02-04
Disclosure Type: Decision on Paid-in Capital Increase (Third-Party Allocation – Redeemable Convertible Preferred Shares)
💡 3-Second Summary
Alteogen has decided to raise approximately KRW 155 billion by issuing Redeemable Convertible Preferred Shares (RCPS) to domestic institutional investors to fund its manufacturing plant construction, headquarters relocation, and operations.
📊 1. [Key Disclosure Content & Major Figures Summary]
- Type & Number of Shares: 434,848 Registered Redeemable Convertible Preferred Shares (RCPS) (Approx. 0.81% of total outstanding common shares prior to issuance)
- Use of Proceeds (Totaling KRW 154,994,177,184):
- Facility Funds: KRW 54,994,177,184 (Approx. KRW 55B / Dedicated to manufacturing plant construction and headquarters relocation)
- Operating Funds: KRW 100,000,000,000 (KRW 100B)
- Issuance Terms & Pricing:
- Issue Price per Share: KRW 356,433 (Priced at a 2.3145% premium over the base stock price of KRW 348,370)
- Voting Rights: Non-voting (Voting rights may be reinstated if resolutions for the agreed preferred dividends are not passed)
- Dividend Rate: 1.0% per annum of the par value (KRW 500) on a cumulative and participating basis
- Redemption & Conversion Conditions:
- Redemption Period: From February 20, 2028, to January 20, 2030 (Exercisable 3 years post-issuance at a 1.0% annual compound interest rate)
- Conversion Period: From February 20, 2026, to January 20, 2030 (Convertible 1:1 into common stock 1 year post-issuance)
- Refixing (Conversion Price Adjustment): Adjusted every 7 months based on market price drops (Floor price set at KRW 302,969, which is 85% of the initial issue price)
- Target Subscribers: Major domestic financial institutions and private equity funds including NH Investment & Securities (72,944 shares), KB-Naus Special Situation Corporate Financial Stability PEF (42,083 shares), and KB-Solidus Healthcare Investment Association (42,083 shares).
- Key Timeline:
- Board Resolution Date: February 4, 2025
- Payment Date: February 19, 2025
- Expected Date of New Share Delivery: March 5, 2025
- Lock-up: Subject to a mandatory 1-year lock-up period at the Korea Securities Depository (No scheduled listing).
📈 2. [Expert View: What This Disclosure Means for Investors]
- Securing Growth Momentum via Infrastructure CapEx: Allocating KRW 55 billion of the raised capital to build a new manufacturing plant and relocate headquarters represents a concrete domestic CapEx expansion. This expansion is likely aimed at preparing for the commercialization phase of its bio-pipeline, signaling a potential positive impact on long-term fundamentals.
- Mitigation of Short-Term Overhang through Strategic Placement: This capital increase relies on a third-party allocation targeting domestic institutional investors rather than a public offering of common shares. Combined with a mandatory 1-year lock-up period, immediate equity dilution or overhang risks on the open market are effectively mitigated.
- Investor Caution: As these are RCPS, the shares can be converted into common stock starting February 20, 2026 (one year after issuance), potentially causing an approximate 0.81% dilution. Investors should also note that if the stock price declines, the refixing mechanism could lower the conversion price down to the KRW 302,969 floor (85% limit), which could subsequently increase the eventual dilution rate.
📝 Editor’s Comment (by K-STOCK Editor)
Alteogen’s KRW 155 billion fundraising carries strategic significance because a substantial portion is earmarked for physical expansion—building a manufacturing plant—rather than merely patching up operational deficits. Notably, major domestic institutions agreed to subscribe at a 2.3% premium rather than a discount, reflecting robust institutional confidence in Alteogen’s valuation. While the 1-year lock-up prevents immediate market disruption, long-term investors should closely track the 7-month refixing cycles and the eventual conversion timeline to monitor the potential dilution impact.
📢 Disclaimer & Source Information
Source: This content was structured and newly written based on the official submitted data from the Financial Supervisory Service Electronic Disclosure System (DART).
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!